Arthritis Foundation Action on CBD for Arthritis Pain
The latest advocacy in action on CBD: New guidance for people with arthritis, a major survey on CBD usage and a comment letter to the FDA
Your shared stories are making a difference every day. This summer, over 2,600 people shared their perspectives on using CBD (cannabidiol) oil, a compound extracted from the cannabis plant, to treat their arthritis pain. These experiences informed our comment letter in July to the Food and Drug Administration (FDA), urging action on product regulation and additional research on CBD.
In addition, on September 24, 2019, we released the Arthritis Foundation CBD Consumer Guidance for Adults With Arthritis. This is the first-ever consumer guidance on the use of CBD for adults with arthritis, developed in partnership with leading experts in CBD and arthritis pain: Dan Clauw, MD, and Kevin Boehnke, PhD, from the University of Michigan; and Mary Ann Fitzcharles, MD, from McGill University in Montreal, Quebec.
In our comment letter, the Arthritis Foundation recommended that the FDA do the following:
• Use its regulatory authority to establish a set of minimum standards all companies that manufacture and market CBD-based products must meet.
• Implement labeling requirements to, at a minimum, differentiate the uses, dosage recommendations and risks of each product.
• Work closely with the National Institutes of Health, other agencies and companies engaged in CBD research to strengthen the level of research and data collection on CBD products and their efficacy and expedite the work, given the percentage of patients already using these products.
• Develop an education initiative to provide trusted, easy-to-use educational tools to consumers.
The Arthritis Foundation will continue to collect patient insights from those with arthritis and has urged the FDA to collaborate with us as a resource to implement the above recommendations.
For a printable PDF, click here.